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Abstract
Osteoporosis is a metabolic skeletal disease characterized by an imbalance between osteo-
clast-mediated bone resorption and osteoblast-mediated bone formation. We examined the
beneficial effect of shock waves (SW) alone or in combination with raloxifene (RAL) on bone
loss in ovariectomized rats (OVX). Sixteen weeks after surgery, OVX were treated for five
weeks with SW at the antero-lateral side of the right hind leg, one session weekly, at 3 Hz
(EFD of 0.33 mJ/mm2), or with RAL (5 mg/kg/die, per os) or with SW+RAL. Sera, femurs,
tibiae and vertebrae were sampled for following biochemical and histological analysis. SW,
alone or combined with RAL, prevented femur weight reduction and the deterioration of tra-
becular microarchitecture both in femur and vertebrae. All treatments increased Speed of
Sound (SoS) values, improving bone mineral density, altered by OVX. Serum parameters
involved in bone remodeling (alkaline phosphatase, receptor activator of nuclear factor
kappa-B ligand, osteoprotegerin) and osteoblast proliferation (PTH), altered by ovariectomy,
were restored by SW and RAL alone or in combination. In tibiae, SW+RAL significantly
reduced cathepsin k and TNF-α levels, indicating the inhibition of osteoclast activity, while
all treatments significantly increased runt-related transcription factor 2 and bone morphoge-
netic-2 expression, suggesting an increase in osteoblastogenic activity. Finally, in bone mar-
row from tibiae, SW or RAL reduced PPARγ and adiponectin transcription, indicating a shift
of mesenchymal cells toward osteoblastogenesis, without showing a synergistic effect. Our
data indicate SW therapy, alone and in combination with raloxifene, as an innovative strat-
egy to limit the hypoestrogenic bone loss, restoring the balance between bone formation
and resorption.
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Introduction
Osteoporosis is a metabolic skeletal disease characterized by low bone mass, deterioration of
bone micro-architecture and increased fracture risk [1]. The prominent prevalence of osteopo-
rosis in Europe (approximately 21% of women aged 50–84 years) and increased mortality rate
in patients with osteoporotic fractures represent a clinical emergency [2, 3]. Postmenopausal
women exhibit the major risk to develop osteoporosis, suggesting that the role of estrogen is
critical in its pathogenesis [4]. Indeed, raloxifene, a selective estrogen receptor modulator
(SERM), has been approved for the prevention and treatment of postmenopausal osteoporosis,
especially because of its capability to prevent or reduce vertebral fractures [5]. However, the
efficacy of this drug in reducing or preventing non-vertebral fractures is strongly limited [6].
The osteoporosis progression is due to an imbalance between osteoclast-mediated bone
resorption and osteoblast-mediated bone formation. The recovery of this balance represents
the rationale underlying the two more recent two anti-osteoporotic strategies: the inhibition of
bone resorption and turnover, and the stimulation of bone formation [7, 8]. Cathepsin k, a
protease abundantly expressed in osteoclasts and in actively resorbing osteoclasts, has been
identified as a novel pharmacological target to counteract osteoporosis by reducing the organic
bone matrix degradation. In particular, two cathepsin k inhibitors, odanacatib and ONO-
5334, have been recently used in clinical trials [9, 10].
To date, the only available agents that stimulate bone formation are the whole molecule par-
athormone (PTH, 1–84) or its fragment, the teriparatide (1–34). Although PTH increases
bone formation through an increase in bone remodeling, its effect is transient and decreases
with time [11, 12]. Moreover, the use of PTH analogues in the clinical practice is limited by
their cost and potential side effects [13].
In the early 80s, shock waves (SW) were used for kidney and urinary stone lithotripsy [14].
Afterwards, SW therapy has been used for the treatment of other orthopedic diseases, acceler-
ating bone healing [15], callus formation [16] and delayed or non-union of long bone fractures
[17]. In addition, SW have been shown to promote the regeneration of alveolar bone in a
rodent model of periodontitis [18]. This therapy is considered a safe and highly versatile tool
to enhance the time of tissue regeneration, in particular on tendon and muscle tissues, also
showing immediate antalgic and anti-inflammatory effects [19].
The biological effects of the SW therapy in bone have been recently examined [20]. Indeed,
Van der Jagt et al. [21] have demonstratedt hat single application of SW has a light beneficial
effect in a rat model of ovariectomy-induced osteoporosis, increasing trabecular bone volume
and reducing bone loss. Additionally, this research group showed that a single application on
tibia induces anabolic effects in cortical bone in normal [22] and osteoporotic rats, especially
when SW treatment was combined with anti-resorptive alendronate therapy [23]. However,
the bone biochemical mechanisms underlying the anti-osteoporotic effects of SW are still
overlooked.
The purpose of this study was to evaluate the modulation of serum parameters and tissue
markers of bone resorption and bone formation in ovariectomized rats after repeated SW ther-
apy, alone or in combination with raloxifene.
Materials and methods
Animals
Female Sprague Dawley rats (Harlan Italy, San Pietro al Natisone, Udine, Italy) were housed in
stainless steel cages in a room kept at 22±1˚C with a 12:12 h light-dark cycle. All procedures
involving the animals were carried out in accordance with the Institutional Guidelines and
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complied with the Italian D.L. no.116 of January 27, 1992 of Ministero della Salute and associ-
ated guidelines in the European Communities Council Directive of November 24, 1986 (86/
609/ECC). All animal procedures reported herein were approved by the Institutional Animal
Care and Use Committee (CSV) of University of Naples Federico II under protocol no. 2013/
0040366. Prior to sample and tissue collection, animals were euthanized by an intraperitoneal
injection of a cocktail of ketamine/xylazine, followed by cervical dislocation to minimize pain.
All efforts were made to minimize animal suffering.
Ovariectomy, Shock Waves (SW) and pharmacological treatment
The experimental design is illustrated in Fig 1. At the onset of the study, female rats (mean
body weight of the cohort: 216.4 ± 1.6 g) were bilaterally ovariectomized (OVX) under anes-
thesia (100 mg kg-1 ketamine plus 5 mg kg-1xylazine ip). The sham-operated (SHAM) animals
were subjected to the same general surgical procedure as OVX groups except for ovarian exci-
sion. After surgery, SHAM and OVX animals received topical antibiotic treatment (with a
preparation containing 0,05 g of neomycin sulfate and 9,95 g of sulfathiazole, for five days).
Fig 1. Experimental scheme. At the onset of the study, female rats were bilaterally ovariectomized (OVX) while the sham-operated (SHAM) animals were
used as controls. After sixteen weeks, rats were divided into five groups: 1) SHAM, receiving drug vehicle; 2) OVX, receiving drug vehicle; 3) OVX treated with
SW once a week for five weeks; 4) OVX, receiving RAL (5 mg/kg/die per os for five days a week for six weeks); and 5) OVX rats treated with SW in
combination with RAL.
doi:10.1371/journal.pone.0171276.g001
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Sixteen weeks after surgery, necessary time for the development of osteoporotic features
[24], rats were divided into the following five groups (n = 6 animals each group): 1) SHAM,
control rats receiving per os drug vehicle; 2) OVX, rats receiving vehicle; 3) OVX+SW, rats
treated with SW one weekly session for five times; 4) OVX+RAL, rats receiving raloxifene (5
mg/kg/die, Lilly Research Laboratories, Indianapolis, USA) per os five days a week for six
weeks; and 5) OVX+SW+RAL, rats treated with SW in combination with the SERM.
Briefly, every week all rats receiving SW were anesthetized with a mix of oxygen and 2%
isoflurane, and the right hind leg was shaved and an ultrasonic gel was applied, as coupling
media. The SW applicator was placed at the antero-lateral side of the right thigh and each ses-
sion of SW treatment consisted in the application of 1000 electro-magnetically generated SW
at 3 Hz with an energy flux densities (EFD) of 0.33 mJ/mm2 (Duolith1 SD1-Storz Medical
AG, Tagerwilen, Switzerland). The focus diameter of the Duolith was 4 mm Full Width at Half
Maximum (FWHM) at the energy used. Non-SW treated animals were also undergone an
anesthesia and shaving without SW application. All animals were euthanized one week after
5th SW application, while last administration of raloxifene was performed 2 h before killing.
During necropsy, we confirmed the effectiveness of OVX surgery, through the evaluation of
uterus weight. Subsequently, bone tissues (treated and contralateral femurs, tibiae, vertabrae)
were sampled and surrounding tissues (skin, muscle and tendons) were removed. Tibiae were
immediately frozen in liquid nitrogen for following molecular analyses of bone tissue and
bone marrow, whereas femurs and lumbar vertebrae were fixed in 10% Neutral Buffered For-
malin (NBF) and subjected to histomorphological examination. Before fixing, femurs were
dried to check their weight, distinguishing SW treated bone from SW-untreated ones.
Body weight gain and fat mass
Throughout the experimental period, body weight was assessed once per week and body
weight gain was calculated as difference between the last measure and the body weight
recorded at the beginning of the experiment. Lastly, values of body weight gain during time
were cumulated and expressed as area under curve (AUC). At the start of necropsy procedure,
bioelectrical impedance analysis was used to assess the rat body composition with the BIA
101analyzer, modified for the rat (Akern, Florence, Italy). Fat-free mass was calculated using
the bioelectrical impedance analysis (50 kHz) prediction equation of Ilagan et al. [25], and fat
mass content was determined as the difference between body weight and fat-free mass.
Analysis of serum parameters
At the start of necropsy procedure, rats were anesthetized by enflurane and blood was collected
by cardiac puncture. Sera were obtained by centrifugation at 1500 x g at 4˚C for 15 min, and
stored at -70˚C for later biochemical and hormonal determinations. Osteoprotegerin (OPG),
Receptor activator of nuclear factor kappa-B ligand (RANKL), and alkaline phosphatase (ALP)
were measured by Enzyme-Linked ImmunoSorbent Assay (ELISA) kits for rats purchased
from Cloud Clone Corp. (Houston, TX, USA), while rat intact PTH (iPHT) levels were deter-
mined by an ELISA kit obtained from MyBioSource Inc. (San Diego, CA, USA). All proce-
dures were performed following the manufacturer’s protocol.
Histological analysis and ultrasonometry
Extracted bones (femurs and vertebrae) were fixed for 3 days in 10% neutral buffered formalin.
Then, the fixed tissues were decalcified with a 4% trichloroacetic acid solution and embedded
in paraffin. Each femur was cut at a 4 micrometer sections through the longitudinal axis, while
each vertebra was cut through the transversal axis. Finally, hematoxylin and eosin (H&E)
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staining was performed for their morphological evaluation. Slides were analyzed using an
optic microscope Nikon Eclipse E600. A blind examination of the sections based on primary
histological analysis of bone (modified from Dempster et al. [26]) was made independently by
two veterinary pathologists (OP and TBP) at high (20X) and low (10X) magnification.
The ultrasound measurements (QUS) were performed using a DBM Sonic 1200 (IGEA,
Carpi, Italy) with an electronic high-precision caliper (± 0,02 mm) where two ultrasound
probes (diameter: 12 mm) are mounted: one probe generates the ultrasound (1,25MHz) and
the other one receives the ultrasound beam after it has crossed the bone specimen. To obtain
the values of speed of sound (SoS, m/s), we used an ultrasonic contact gel along the longitudi-
nal axis of animal femurs. After four measurements, the speed of sound (SoS, m/s) was calcu-
lated after four measurements in order to reduce repositioning errors, as previously described
[27].
RNA extraction and Real-time semi-quantitative PCR
Tibiae were dissected from the rats and cleaned with 0.1 M ice-cold PBS, pH 7.2. For OVX
+SW and OVX+RAL+SW groups, both contralateral and SW-treated tibiae were used. The
epiphysis of each bone was excised and the bone marrow was collected [28]. Bone tissues were
snap-frozen in liquid nitrogen to make them breakable. Total RNA was extracted using TRIzol
Reagent (Bio-Rad Laboratories), according to the manufacturer’s instructions. cDNA was syn-
thesized using a reverse transcription kit (NucleoSpin1, MACHEREY-NAGEL GmbH & Co,
Du¨ren, Germany) from 2 μg total RNA. PCRs were performed with a Bio-Rad CFX96 Connect
Real-time PCR System instrument and software (Bio-Rad Laboratories). The PCR conditions
were 15 min at 95˚C followed by 40 cycles of two-step PCR denaturation at 94˚C for 15 s,
annealing at 55˚C for 30 s and extension at 72˚C for 30 s. Each sample contained 1–100 ng
cDNA in 2X QuantiTect SYBRGreen PCR Master Mix and primers, TNF-α, RANKL, OPG,
Bone morphogenetic 2 (Bmp2), runt-related transcription factor 2 (RUNX2), cathepsin k, Per-
oxisome proliferator-activated receptor gamma (PPARγ) and adiponectin (both by Qiagen, Hil-
den, Germany) in a final volume of 50 μl. The relative amount of each studied mRNA was
normalized to GAPDH as housekeeping gene, and data were analyzed according to the 2-ΔΔCT
method.
Statistical analysis
All data were presented as mean ± SEM. Statistical analysis was performed by ANOVA test for
multiple comparisons, followed by Bonferroni’s test. Statistical significance was set at P<0.05.
Results
Body parameters
As depicted in Fig 2A, weight gain of OVX+RAL+SW group decreased during time and was
significantly lower than OVX rats after 5 weeks of the combined treatment (21th week). RAL
treatment of OVX rats showed a decreasing trend in body weight gain compared to OVX
group. Weight gain of OVX+SW did not differ significantly from OVX group. All these data
were confirmed by AUC of weight gain during the treatment time (Fig 2B). As shown in Fig
2C, fat mass, measured at 22th week, was significantly increased in the OVX rats, compared
with the SHAM animals, while the treatment with RAL or its association with SW reduced it.
The femurs of rats were weighed after excision, discerning the SW treated from untreated
bone (Fig 2D). The SW+RAL associated treatment significantly improved the remarkable loss
of bone weight of OVX animals.
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Bone histology and serum remodeling markers
We evaluated histomorphology of vertebrae (V) and femurs (F) excised from all rats. Trabecu-
lar thickness and organization, and adipose tissue infiltration in bone marrow were examined
(Fig 3A). OVX rats showed, as expected, a reduced thickness and organization of vertebra and
femur trabeculae, and an increased amount of adipose tissue infiltration compared with
SHAM group. In particular in vertebrae, SW and its combination with RAL induced a reduc-
tion of adipose tissue infiltration and an improvement of trabecular thickness and organiza-
tion compared with OVX. The same parameters were also analyzed on femur metaphyses,
distinguishing SW treated and contralateral limb (Fct). Thickness and organization of meta-
physeal trabeculae were remarkably ameliorated by SW or RAL alone and notably their combi-
nation restored trabecular structure as that of SHAM, without difference between SW treated
and contralateral limb.
By the quantitative ultrasound measurement, we calculated the SoS of the femur of all ani-
mals. OVX rats showed a significant decrease of SoS than SHAM group, improved by all
Fig 2. Effects of SW and RAL treatment on body weight gain (A), also expressed as AUC of cumulative weight gain during time (B), fat
mass (C) and femur weight (D) are shown. Body weight gain was monitored every week, during all experimental time. Femur weight was
determined in contralateral (-) and SW-treated (+) of OVX+SW and OVX+RAL+SW animals. Values are expressed as means ± SEM
(n = 6); *P <0.05, **P <0.01 and ***P <0.001 compared with SHAM; #P <0.05, ##P <0.01 and ###P <0.001 compared with OVX.
doi:10.1371/journal.pone.0171276.g002
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treatments (SHAM, 1931± 6,85; OVX, 1826 ± 4,251

; OVX+SW, 1867 ± 9,291 #; OVX+RAL,
1887 ± 13,58 ###; OVX+SW+RAL, 1864 ± 5,37 #;

p<0,001 vs SHAM; # p<0,05 and ###
p<0,001 vs OVX).
Serum parameters involved in bone formation or osteoblast proliferation, S-ALP and iPTH
respectively, were examined (Fig 3B and 3C). Both markers were modulated by all treatments
and in particular SW+RAL was able to significantly restore their levels. Moreover, we showed
that treatments with SW, RAL and their combination increased OPG/RANKL ratio showing a
reduction of the osteoclastogenic process (Fig 3D).
SWs alone or combined with RAL modulate genes involved in bone
formation and resorption
To confirm the involvement of OPG/RANKL in the effect of SW and RAL, we also evaluated
their mRNA expression by Real Time PCR in tibiae. OVX group showed a significant reduc-
tion of OPG/RANKL ratio compared with SHAM, that was significantly increased by SW and
RAL, alone or in combination (Fig 4A), indicating a reduction in bone resorption.
Fig 3. Effects of SW and RAL treatment on histological features of vertebrae (V), femural metaphyseal bone (F) and contralateral femurs (Fct) of SHAM (A,F,
K), OVX (B,G,L), OVX+SW (C,H,M), OVX+RAL (D,I,N) and OVX+SW+RAL (E,J,O) groups (panel A). Bone sections were stained with H&E to visualize
trabecular thickness and organization, and adipose tissue infiltration in bone marrow. Effects of SW and RAL treatments on bone markers in serum: ALP
(panel B), iPTH (panel C) and OPG/RANKL ratio (panel D). Values are expressed as means ± SEM (n = 6); **P <0.01 and ***P <0.001 compared with
SHAM; #P <0.05, ##P <0.01 and ###P <0.001 compared with OVX.
doi:10.1371/journal.pone.0171276.g003
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Consistently, OVX animals showed a significant increase of TNF-α which stimulates osteoclast
proliferation, while all treatments remarkably reduced its transcription (Fig 4B). Fig 5 showed
the mRNA expression of cathepsin K, Bmp2, andRUNX2. OVX caused a marked increase of
cathepsin K compared with SHAM; SW and RAL alone showed a trend of enzyme reduction
that reached significance when combined (Fig 5A). Moreover, SW and RAL alone or com-
bined increased Bmp2 mRNA expression(Fig 5B), while SW or RAL alone increased RUNX2
transcription, that was less affected by their combination(Fig 5C).
Modulation of PPARγ and adiponectin transcription in tibial bone marrow
by SW alone or combined with RAL
Hypoestrogenism in rodent, as well as in human, was found to be associated with increased
bone marrow adiposity [29, 30]. Consistently, we showed an increase in PPARγ and adiponec-
tin mRNAs in bone marrow of tibiae from OVX (Fig 6A and 6B). Both treatments either SW
or RAL significantly reduced the transcription of both genes. Conversely, SW and RAL combi-
nation did not significantly modify OVX-induced increase in PPARγ and adiponectin
mRNAs, although a trend of decrease of PPARγ expression was found.
Discussion
In the present study we show the beneficial effect of SW therapy, alone or in combination with
raloxifene, inducing bone formation and reducing bone resorption impaired by OVX.
Postmenopausal hypoestrogenism triggers the events involved in the osteoporotic process:
massive bone resorption entailing loss of bone mass and architecture and failure to replace lost
bone due to remarkable reduction of bone formation [4]. The ovariectomized rat is a standard
preclinical model in the development of anti-osteoporosis therapies, reproducing molecular
and biochemical alterations of the pathology [24, 31].
Our hypothesis regarding the benefits of SW treatment in osteoporosis was suggested by
previous data demonstrating that a single SW application could be effective increasing trabec-
ular bone volume and reducing bone loss [21], especially when it was combined with anti-
resorptive alendronate therapy [23]. Here, we demonstrate the efficacy of repeated SW
Fig 4. Effect of SW and RAL treatments on bone resorption parameters in tibiae. mRNA of OPG/RANKL ratio (A) and TNF-αare shown (B).
For OVX+SW and OVX+RAL+SW groups, contralateral and SW-treated tibiae were used. Values are expressed as means ± SEM (n = 6); **P
<0.01 compared with SHAM; #P <0.05, ##P <0.01 and ###P <0.001 compared with OVX.
doi:10.1371/journal.pone.0171276.g004
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Fig 5. Effects of SW and RAL treatments on bone remodeling balance: cathepsin K (A), Bmp2 (B) and
RUNX2 (C) mRNA expression are shown. For OVX+SW and OVX+RAL+SW groups, contralateral and SW-
treated tibiae were used Values are expressed as means ± SEM (n = 6); **P <0.01 compared with SHAM; #P
<0.05, ##P <0.01 and ###P <0.001 compared with OVX.
doi:10.1371/journal.pone.0171276.g005
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applications alone or combined with raloxifene (for 6 weeks) on osteoporosis induced by long
term ovariectomy. As previously described [31], and here confirmed, 22 weeks ovariectomy
clearly led to a significant increase in body weight and fat mass, and raloxifene reduced fat
mass by its estrogenic activity. In our experimental conditions RAL, administered when ovari-
ectomy-induced hypoestrogenism was defined, reduced also significantly weight gain only in
association with SW treatment.
Interestingly, when RAL is associated with SW, a synergistic effect is also shown on femur
weight since this parameter raised significance only in SW+RAL-treated rats both in SW
treated and contralateral femur, indicating a lower bone loss than in OVX animals. In addi-
tion, all treatments were able to increase the values of SoS reduced by OVX, indicating an
improvement of bone mineral density (BMD).As previously demonstrated, QUS technique is
significantly comparable to the dual X-ray absorptiometry (DXA), the main used technology
for BMD evaluation [32].
The capability of both treatments in restoring bone architecture was also evidenced by his-
tological analysis. All SW-based treatments were more effective than RAL in reversing histo-
logical features of osteoporosis showed in OVX rats, not only in vertebrae but also in treated
and contralateral femurs. The evaluation of trabecular architecture in osteoporotic metaphy-
seal femur shows its considerable improvement after repeated weekly applications of SW. This
effect was more evident after combined therapy. We also observed an increase of adipose infil-
tration in OVX group compared to control and treated groups, not only in femur but also in
vertebrae. No differences between treated and contralateral limbs were noticed in SW alone or
combined with RAL, supporting the hypothesis of a systemic effect of SW therapy.
Many key factors regulate the balance between bone resorption and formation. Osteoclasto-
genesis is stimulated by the binding between RANK and RANKL, expressed in osteoclast pro-
genitor cells and osteoblasts, respectively. RANKL-RANK interaction is prevented by the
natural RANKL inhibitor, OPG. Clinical and experimental studies demonstrated that estro-
gens increase mRNA and protein expression of OPG and decrease RANKL and macrophage
colony-stimulating factor (M-CSF) expression [33, 34]. In our experimental model, we
Fig 6. Modulation of PPARγ and adiponectin transcription in tibial bone marrow by SW alone or combined with RAL. PPARγ
(A) and adiponectin (B) mRNA expression are shown. For OVX+SW and OVX+RAL+SW groups, contralateral and SW-treated tibiae
were used. Values are expressed as means ± SEM (n = 6); **P <0.01 compared with SHAM; ##P <0.01 compared with OVX.
doi:10.1371/journal.pone.0171276.g006
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demonstrate that not only RAL, but also SW and their association inhibit osteoclastogenesis,
modulating OPG/RANKL ratio both in serum and bone tissue, remarkably altered by 22 week
ovariectomy. Moreover, all treatments significantly reduce the TNF-α mRNA expression in
tibiae, and this cytokine, as well as IL-1 and PGE2, has been identified as regulator for osteo-
clast activity [35]. TNF-α presents anti-apoptotic activity on osteoclasts, increasing their life-
span [36] and synergistically with RANKL stimulates osteoclastogenic activity [37], inducing
osteoclast formation and bone resorption both directly and increasing the sensitivity of matur-
ing osteoclasts to RANKL. TNF-activated pathways and mechanisms involved in bone remodel-
ing remain partially unclear; in fact, a recent review summarized the paradoxical role of TNF-α
on bone homeostasis and bone remodeling imbalance involved in systemic/vertebral osteoporo-
sis [38]. Other studies will be necessary to explain the lack of synergistic effect between SW and
RAL on TNF-α in bone. A possible competitive effect between the two treatments, by unidenti-
fied endogenous endocrine or paracrine factors on bone, can not be excluded and should be
clarified.
On the other hand, the association SW+RAL significantly reduces cathepsin k levels, a
prominent lysosomal cysteine protease that is involved in bone degradation of extracellular
matrix proteins, such as elastin and collagen [39]. Few years ago, it was demonstrated that two
cathepsin K inhibitors prevented bone loss with similar efficacy to that of alendronate in estro-
gen-deficient rabbits, but, unlike bisphosphonates, had no suppressive effect on bone-forma-
tion rate at trabecular and cortical bone sites suggesting better long term benefits than the
current standard of cure [40]. To date, odanacatib and ONO-5334 are currently in clinical
development, as new reliable strategy for osteoporosis treatment [41].
Approximately thirty Bmps members of transforming growth factor-β superfamily have
been identified and characterized, among which Bmp2 is recognized as a pivotal signal in regu-
lating osteoblastogenesis [42]. Several studies using transgenic mice have shown that Bmp2
functions as a fundamental component of the inherent regenerative capacity of bone [43].
Bmps are used locally for the treatment of non-union fractures and proteosome inhibitors
enhancing Bmp2 expression may have an effect on bone tissue and have been proposed as
potential anabolic therapies [8]. The involvement of NO pathway in SW osteogenic effect was
previously reported in vitro [44], evidencing an increase in Bmp2 and RUNX2 transcription in
marrow stromal cells of hips with osteonecrosis. Here, we evidenced that SW and their associa-
tion with RAL increase mRNA Bmp2, indicating their effects on bone regeneration, compro-
mised in OVX rats. This data was strengthened by the significant increase in serum iPTH level
induced by SW plus RAL, supporting the stimulatory effect on bone formation of the com-
bined therapy.
During bone remodeling, beyond the resorptive role of osteoclasts, new bone is formed by
osteoblasts derived from mesenchymal stem cells [45]. These latter ones could also differenti-
ate into adipose cells, as it can occur during bone loss through an expansion of adipose tissue
in the bone marrow [46]. Among factors having contrary effects on both differentiation path-
ways,RUNX2 is master transcription factor for osteogenesis [47], while PPARγ is designated
to induce adipogenesis [48]. Interestingly, SW and RAL not only markedly increased the tran-
scription of RUNX2 in bone, but also reduced PPARγ levels in bone marrow, indicating the
shift of MSCs from adipogenesis to osteogenesis. This hypothesis was confirmed by the reduc-
tion of adiponectin in bone marrow from SW and RAL treated animals. In fact, clinical studies
showed that high levels of adiponectin are associated with a reduction of bone mineral content
and body mineral density [49, 50], that also confirmed in mouse models [51]. Clinical post-
menopausal estrogen insufficiency was found to be associated with increased bone marrow
adiposity [30], while the observed increase in marrow adipogenesis could be prevented or
reversed by estrogen replacement both in humans and rats [29]. Our data confirm previous
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results showing that adipogenesis induced by OVX is a reversible process which can be cor-
rected by estrogen, phytoestrogens, or raloxifene treatments [52], and for the first time we
demonstrate the reduction of adipogenesis in rat bone marrow after repeated SW application.
Interestingly, the lack of the synergic or additive effects by SW and RAL on adipogenesis/oste-
ogenesis balance could represent a limit of their interplay; indeed, a possible competitive effect
by unidentified endogenous endocrine or paracrine factors involved in their respective mecha-
nism of action at bone marrow level can be considered.
In conclusion, our study demonstrates the beneficial anti-osteoporotic effects of SW ther-
apy, alone or in combination with raloxifene, evidencing their strengths and limits. The mech-
anisms of these effects can be a result of the increase of bone formation and the reduction of
bone resorption. Combined or multi-target therapies are a common approach in the treatment
of chronic and multifactorial diseases, such as osteoporosis. SW therapy is considered a non-
invasive therapeutic modality with effectiveness, convenience, and safety; also replacing sur-
gery with no surgical risks in many orthopedic disorders [20, 53] and it may represent an inno-
vative strategy to limit the progression of osteoporosis.
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